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Abstract
Background: Following the World Trade Center disaster, a large number of individuals involved in rescue and
recovery activity were exposed to significant amounts of dust, and reported symptoms of chronic nasal and sinus
inflammation. An unusually high prevalence of obstructive sleep apnea (OSA) has also been observed in this World
Trade Center Responder population. This project aims to examine the relationship between nasal pathology and
OSA. Our hypothesis is that increased nasal resistance due to nasal inflammation predisposes to OSA in this
population. Continuous Positive Airway Pressure (CPAP) is the standard therapy for OSA but despite its efficacy has
poor adherence. Subjects with high nasal resistance may have greater difficulty in tolerating this therapy than those
who do not have high nasal resistance. Reduction of excess expiratory positive pressure by the modality known as
Cflex™ during Continuous Positive Airway Pressure therapy (CPAPFlex) has been suggested to improve comfort
without compromising efficacy. We will compare CPAP to CPAPFlex in subjects with OSA.
Study Design: Subjects with new onset habitual snoring will be screened for OSA using home sleep studies
and rhinomanometry will be used to determine nasal resistance. In 400 subjects with OSA we will perform a
randomized double blind cross-over study comparing CPAP to CPAPflex, and relate nasal resistance to adherence
to CPAP therapy.
Discussion: This is the first multicenter trial designed to test the hypothesis that adherence to CPAP therapy relates
to nasal resistance and CPAPFlex will improve adherence to CPAP in those subjects with high nasal resistance.
We anticipate the following results from this trial: 1. Increased nasal resistance is associated with decreased
adherence to CPAP therapy. 2. Use of CPAPFlex improves adherence with CPAP therapy in subjects with high nasal
resistance, but not in those with low nasal resistance. 3. The benefit of CPAPFlex on adherence is greatest when
offered at CPAP therapy initiation rather than as a “rescue” therapy in subjects with high nasal resistance.
Trial Registration: ClinicalTrials.gov Identifier: NCT01753999, Date: 12 December 2012
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Background
Following the World Trade Center (WTC) disaster on
11 September 2001, an estimated 40,000 individuals in-
cluding fire fighters, police and other public sector
workers were exposed to significant amounts of dust
while working in rescue, recovery and debris removal
[1]. A medical screening program was developed to
evaluate the health status of workers and volunteers who
spent time at the WTC site and sustained exposure in
the aftermath of 11 September.
The WTC Worker and Volunteer Medical Screening
Program (MSP) and the follow-up World Trade Center
Medical Monitoring and Treatment program (WTCMMP)
now called the World trade Center Health program
(WTCHP) have successfully recruited more than 27,000
responders to assess and treat health effects from these ex-
posures [2]. About 1700 of these responders are followed
at the Environmental and Occupational Health Sciences
Institute (EOHSI) of Rutgers Robert Wood Johnson
Medical School (RWJMS) in Piscataway, New Jersey and
about 2100 in the NYU School of Medicine Clinical
Center of Excellence (NYUSOM CCE) at Bellevue Hos-
pital in New York City. Standardized questionnaires
were completed by these responders. These question-
naires provide the medical history and presence of new
symptoms following the exposure and the presence of
diseases such as OSA.
The collapse of the WTC towers resulted in a massive
plume of building debris and particulate dust that was
highly alkaline and corrosive and contained high levels of
calcium sulfate (gypsum) and calcium carbonate (calcite)
that are capable of causing chemical irritation to the upper
respiratory tract and irritation of mucous membranes [3, 4].
Obstructive sleep apnea (OSA)
OSA is a chronic condition with recurrent episodes of
partial or complete upper airway collapse during sleep.
The main risk factors for OSA are obesity and male gen-
der and it is highly prevalent in the general population,
with estimates ranging from 5–10 % to > 25 % [5, 6].
Upper airway inflammation resulting in mucosal conges-
tion and edema could increase nasal and posterior
pharyngeal resistance and provide an alternate mechan-
ism for development of compromised upper airway pa-
tency during sleep. We hypothesize that WTC dust
exposure results in upper airway and nasal inflamma-
tion, leads to nasal symptoms and increased nasal resist-
ance and ultimately to OSA.
The health benefits of diagnosis and treatment of OSA
are well recognized: untreated OSA is associated with
daytime sleepiness, increase in motor vehicle accidents, in-
creased hypertension, stroke, impaired glucose metabolism,
and increase in all-cause mortality [7, 8]. CPAP is the pri-
mary treatment for OSA [9]. CPAP use normalizes sleep
architecture, reduces daytime sleepiness, and reduces
automobile accidents and lowers blood pressure slightly
(2–3 mmHg) and may reduce cardiovascular events
[10–14]. Despite its efficacy, 29–83 % of patients are
non-adherent to CPAP [15] and no specific factors
(demographic, disease specific) that predict CPAP ad-
herence have been identified. In addition to problems
with the mask and claustrophobia, pressure intolerance
and “difficulty exhaling” are frequently cited by patients
as limiting acceptance of CPAP therapy [15]. Nasal
symptoms and side-effects are also common and may
account for 30–50 % of cases of CPAP intolerance [16].
Thus, in addition to its role in causing OSA [8], ele-
vated nasal resistance may impact on initial acceptance
of CPAP [17, 18]. Small studies [16] have shown that
nasal resistance was significantly higher in OSA pa-
tients who did not tolerate CPAP and reduction of
nasal resistance by surgery [19] has been shown to in-
crease CPAP use. CPAP adherence in WTC responders
with chronic rhinosinusitis is unknown but in general
has anecdotally been thought to be poor. High nasal re-
sistance can play a potential role in their poor adher-
ence. CPAP keeps the upper airway open and nasal
resistance becomes the primary determinant of total
upper airway resistance. Thus, during CPAP use, high
nasal resistance may continue to cause a patient to
experience discomfort while exhaling despite adequate
relief of OSA and could contribute to intolerance of
CPAP. In preliminary data we have shown that, as ex-
pected, increased nasal resistance results in higher expira-
tory pressure. By decreasing this excess pressure during
the expiratory cycle, CPAPFlex (Philips Respironics, Murry
Ridge Lane, Murrysville, PA) may improve CPAP adher-
ence. Although prospective, randomized studies have
demonstrated that CPAPFlex is not inferior to conventional
fixed CPAP, increased adherence has not been uniformly
demonstrated. Some studies have shown CPAPFlex reduces
discomfort and improves adherence [20], but larger ran-
domized studies [21] have shown no difference in adher-
ence between CPAP and CPAPFlex. However, none of
these studies have attempted to target therapy to patients
based on elevated nasal resistance as we propose to do.
Study rationale
In this study we will relate nasal resistance to CPAP ad-
herence in patients with OSA and show that reduction
of expiratory pressure using CPAPFlex will improve
CPAP adherence. Patients with OSA will be randomized
in a double blind cross-over design to receive CPAP or
CPAPFlex and adherence will be measured.
We will test the hypotheses that:
 Increased nasal resistance is associated with
decreased adherence to CPAP.
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 Use of CPAPFlex will improve adherence with CPAP
in subjects with high nasal resistance, but not in
those with low nasal resistance.
 The benefit of CPAPFlex on adherence will be
greatest if it is offered at CPAP initiation rather than




This study is a two-center double blind randomized con-
trol trial with a cross-over design in WTC responders
with OSA comparing CPAP to CPAPFlex (See Fig. 1).
Ethical aspects
The study protocol and patient information documents
have been approved by the Institutional Review Board of
both NYU School of Medicine (NYU SOM, IRB Protocol
#S12-02578) and Rutgers Robert Wood Johnson Medical
School (Rutgers RWJMS, IRB Protocol #2012002164) and
the Population Protection Committee of the WTCHP.
Informed consent is obtained from each subject prior to
participation in the study.
Study population and clinical evaluation
We will study a total of 400 subjects with OSA (200 at
each site) from the Clinical Centers of Excellence (CCE)
for responders (n = 2100) at NYU SOM and at EOHSI,
Rutgers RWJMS (n = 1700). Recruitment for the study
began in March of 2013 and will continue until August
of 2016.
Inclusion criteria: 1) Member of the WTCHP at NYU
SOM or Rutgers RWJMS, 2) OSA diagnosed on the
basis of a 2-night home sleep study.
Exclusion criteria: (i) Gross skeletal alterations affect-
ing the upper airway (eg. Micrognathia), (ii) Unstable
chronic medical conditions known to affect OSA (con-
gestive heart failure, stroke), (iii) Pregnancy or intent to
become pregnant within the period of the protocol, (iv)
Inability to sign informed consent form, (v) habitual
snorer or diagnosis of OSA prior to 11 September 2001.
Objective assessment of nasal pathology
Clinical examination
Anterior rhinoscopy is performed to identify erythema,
edema, polyps or polypoid swelling, crusting, mucin, and
or frank pus and documented.
Rhinomanometry
In 2005, the Standardization Committee on Objective
Assessment of the Nasal Airway recommended that 4-
phase rhinomanometry be adopted as the universal stand-
ard for measurement of nasal resistance [22]. It consists of
simultaneous measurement of airflow through the nose
and differential pressure required for its generation. By
dividing inspiration and expiration into increasing and de-
creasing phase, high-resolution rhinomanometry (HRR)
introduces two new parameters: effective resistance and
Fig. 1 Protocol flow chart. Simplified illustration of the protocol for all participants. CPAP, continuous positive airway pressure; CPAPFlex, continuous
positive airway pressure with reduced pressure during expiration OSA, obstructive sleep apnea
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vertex resistance and has been validated in normal and
pathological individuals. We assess nasal resistance
using the 4-phase-rhinomanometer (RhinoLab GmbH,
Rendsburg, Germany) following the detailed technical,
practical methodology, and referenced normative data
published in the literature [22]. Measurements are per-
formed seated and in the supine position (before and
10 minutes after decongestion with 0.1 % xylometazo-
line solution) in a quiet procedure room with a con-
stant temperature. Parameters obtained from the HRR
include the unilateral effective and vertex resistances
during inspiration, expiration and during the entire
breath. “Effective Resistance (Reff )” describes the com-
puterized measurement and calculation of 2000 effec-
tive flow and differential pressure measurements
recorded for each averaged breath. “Vertex Resistance” is
the resistance of the nasal airstream at the point of max-
imum flow during inspiration or expiration in a breath.
Total nasal resistance is calculated using Ohm’s law mod-
eling the nose as parallel resistors using the following
formula:
Total Nasal Resistance ¼ Rright  Rleft= Rright þ Rleftð Þ:
Effective and vertex resistance will be presented
after the recommended logarithmic transformation.
Log Reff ≤ 0.8 is defined as low resistance and > 0.8 as
moderate-high resistance.
Home monitoring for OSA
Subjects are given an ARES™ Unicorder (Watermark
Medical Inc., West Palm Beach, FL, USA) to take home
and wear for two nights, with a pre-addressed mailer to
return the device to the sleep lab. The ARES Unicorder
is worn on the forehead and does not require additional
wires to external devices. It measures oxygen saturation
and pulse rate from reflectance oximetry, airflow from a
nasal cannula/pressure transducer, snoring via acoustic
microphone and head movement actigraphy and head
position from accelerometers. The device also provides
audible alerts during the study if poor quality airflow or
SpO2 is detected so the subject can reposition the
device.
Analysis of respiratory data from ARES
Data from the monitor is autoscored and then manually
reviewed by a single trained sleep technician at NYU
SOM. There has been significant evolution of the defin-
ition of OSA in the epidemiological literature since the
landmark study of Young et al. [5], where a reported in-
cidence of 2–4 % was based on an Apnea + Hypopnea
Index (AHI) > 5/hour and symptoms of excessive day-
time somnolence. Apneas are scored when there is a
reduction in airflow to less than 10 % of baseline.
Hypopneas4 % are scored for > 30 % reduction in airflow
associated with 4 % or more decrease in oxygen satur-
ation. In most of the studies since, including the Sleep
Heart Health Study [23], hypopnea has been defined as a
reduction in airflow amplitude associated with desa-
turation and/or arousal, but the prevalence of OSA is
five-fold greater when arousals are included without as-
sociated desaturation. The American Academy of Sleep
Medicine has issued several definitions of OSA, most re-
cently in 2007 [24] but all require an electroencephalo-
gram (EEG) and there is no published consensus as to
how to score home monitoring without EEG. The ap-
proach we take is to use AHI4 % (nearly identical to the
recommended AHI of the AASM AHI) and to define the
Respiratory Disturbance Index (RDI) as the sum of AHI4
% and the more subtle respiratory events (Hypopnea 1 %,
which approximates the AASM “RERAs” or Respiratory
Effort Related Arousals defined with an EEG). Hypopneas
1 % are scored for > 30 % reduction in airflow associated
with 1 % decrease in oxygen saturation/or surrogate of
arousal. AHI 4 % is calculated as apneas + hypopneas4 %
divided by total valid recording time. The RDI is calcu-
lated as apneas + hypopneas4 % + hypopneas1 % divided
by total valid recording time. Using these metrics, we
define OSA as present when AHI 4 % > 5/hour or when
RDI > 15/hour. We have extensive experience using the
ARES device and have validated it against NPSG in
over 300 subjects in multiple research studies [25, 26].
In our published validation study the diagnostic sen-
sitivity for diagnosing OSA using a cutoff for RDI of
15/hour ranged from 85–95 % and specificity from
91–94 %. Of particular note the failure rate for acquir-
ing scorable data is < 10 % [25].
We have previously compared ambulatory studies per-
formed with the ARES to laboratory NPSG [25, 27], and
shown that, with the ARES, AHI4% is well measured
and AHI1% is functionally equivalent to the RDI.
Intervention
1. From the ambulatory ARES studies, we expect to
identify approximately 750 subjects with OSA and plan
on recruiting 400 subjects for the CPAP/CPAPFlex trial.
All subjects willing to try CPAP are recruited to
undergo titration and measures of nasal resistance.
Participants are randomly assigned to CPAP or
CPAPFlex as a first treatment, and crossed over to the
other after completing the first arm of the protocol.
2. Titration of the assigned therapy is in the home with
AutoCPAP with CPAP or CPAPFlex over 5 days.
Prescribed therapy is at the 90th centile of
autotitration pressure after this period if the subject
uses the machine for more than 4 hours a night on
each of those nights. If fixed pressures are not
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achieved by the end of the first week, the subject is
left in the autotitration mode.
3. Adherence is continuously monitored via the modem
connected to the CPAP and/or the CPAP compliance
card for 1 month with first intervention, then
switched to the alternate intervention and adherence
monitored for another month. Data from the last
2 weeks of each period will be used for objective
adherence comparisons between interventions.
4. Subjective assessment of sleepiness, quality of life
and satisfaction with therapy are obtained using
questionnaires administered at the start and end of
each period.
Initiation of therapy
After results of the ambulatory monitoring identify
OSA, subjects return to the study center for discussion
with study staff regarding therapy. If they agree to CPAP,
they undergo mask-fitting and desensitization and CPAP
education during this visit. CPAP education follows a
written protocol common to both sites. During the first
week, the research co-coordinator calls the patient twice
(day 3 and day 7) to discuss any mask or CPAP-related
issues. Period 1 of the intervention begins subsequent to
this break-in week and lasts for 4 weeks. Treatment is
switched remotely and period 2 of the intervention
begins subsequent to that and last 4 weeks.
Randomization and blinding
OSA patients are randomly allocated to CPAP or CPAP-
Flexstratified by site and low (log[Reff] ≤ 0.8) and high
(log[Reff] > 0.8) resistance, gender and AHI (> or < 30
events per hour of sleep) by the statistician. This is ac-
complished by a computer generated allocation table
of randomly permuted blocks of assignments to study
condition (CPAP or CPAPFlex) for each site. Outcome
of the randomized choice of treatment is provided to
an unblinded individual who is not part of the analysis
of the study data, when a subject arrives to the center,
and who remotely sets the allocated CPAP device at
the start of each treatment period. Devices are tracked
by serial number. Trial participants are blinded to the
therapy type but may be able to perceive a difference
in the mask pressure during expiration. CPAP and
CPAPFlex machines are identical otherwise and no
feedback is provided to subjects regarding the type of
treatment. All investigators and research personnel
who enroll and interact with the participants, outcomes
assessors and data analysts are blinded to the intervention
and allocation as it is remotely set and not evident on the
device. The unblinded individual (not the PI) maintains a
master password protected file containing the serial num-
ber, patient ID and designation code for each treatment
period and subject. Except in a medical emergency
situation this file will not be opened until the study has
been completed and all data have been entered/cleaned.
The unblinded individual will document any premature
unblinding that may occur. The unblinded individual also
reviews the data relevant to treatment efficacy during the
first 5 days of autotitration and significant deviations from
prescribed pressure due to leak during the rest of the
intervention period.
AutoCPAP titration
All subjects diagnosed with OSA are given an autotitrating
machine. We use the Respironics AutoCPAP device which
has capability of autotitration of pressure with or without
Cflex set at a level 3. The devices communicate with the
sleep centers via modem or broadband (HIPPAA- compli-
ant). The auto-titrating positive airway pressure (APAP)
with a range of pressures from 5–15 cm H2O with or with-
out CPAPflex is set when the subject presses a modem
button after turning on the machine at home. These ma-
chines have been used extensively [28, 29] and are used to
determine a single optimal pressure after a period of auto-
titration. During the first 5 days of autotitration, summary
raw airflow data collected are reviewed by an unblinded
technician (see blinding above) to ensure efficacy of treat-
ment. After 5 nights of at least 4 hours of use, the device
automatically switches to a fixed pressure from the 90th
percentile of pressures achieved and used for the remain-
der of the study. Patients who are non-compliant (use for
less than 4 hours a night) during the first 5 nights remain
on autotitrating pressures. The automated AHI is moni-
tored to ensure efficacy of therapy (AHI of < 10 events per
hour of sleep). If the AHI is > 10 events per hour of sleep
the data is reviewed by a designated unblinded sleep phys-
ician and the pressure is modified or the patient is recom-
mended for an in laboratory sleep study if indicated. All
patients are provided heated humidification.
Primary outcome measure
In this intention-to-treat study, primary data to be col-
lected will be adherence with therapy (hours of usage at
set pressure) per night, and residual AHI on treatment.
Those patients who are diagnosed with OSA but who re-
fuse to come in for CPAP therapy will be excluded from
analysis. Primary outcome measure will be mean hours
of usage at set pressure per night during the last 2 weeks
of the intervention.
Monitoring of CPAP efficacy and adherence
Efficacy will be evaluated by (i) reviewing residual AHI
and inspiratory flow limitation at optimal pressure as
recorded on the device and (ii) review of raw airflow sig-
nal. Nightly adherence at the optimal pressure is recorded
on the device and also transmitted to the sleep center onto
a HIPPAA-compliant website that is password protected.
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Cross-over to alternate therapy
Four weeks after the fixed pressure is achieved following
the first intervention (ie CPAP or CPAPFlex), the device
will be switched to the alternate mode by remote
modem connection and the autotrial is started again.
This duration was chosen because long-term CPAP
adherence has been consistently shown to be predicted
primarily by early short-term CPAP adherence [30–33].
Subjective assessment
At the end of each intervention period subjects will fill
out the Epworth Sleepiness Scale (ESS), Functional Out-
come of Sleep Questionnaire (FOSQ) and a satisfaction
questionnaire [29].
Analysis plan and statistical considerations
Power analysis
We will randomize 400 subjects with OSA, stratified by
nasal resistance, into two sequences of treatment: CPAPFlex
followed by CPAP alone versus CPAP alone followed by
CPAPFlex. To determine if high nasal resistance is associ-
ated with decreased CPAP adherence, we based our power
analysis on the method of Fisher’s Z test [34] for correl-
ation coefficients. With 400 participants and setting alpha
at 0.05 (2-sided), we will have 80 % power to test a small
(negative) correlation of −0.14. To determine if use of
CPAPFlex will improve adherence with CPAP in subjects
with high nasal resistance, but not in those with low nasal
resistance, we assume that 50 % of our subjects (200) will
have high nasal resistance, based on our pilot data in non-
WTC subjects. In Aloia et al. [20], they found that CPAP-
Flex significantly improved adherence of CPAP at 4 weeks
(3.5 ± 2.8 hours for CPAP and 4.7 ± 2.2 hours for CPAPFlex
corresponding to Cohen’s d of 0.49). Assume that the ef-
fect size of CPAPFlex improvement between high versus
low nasal resistance is 80 % of the effect of Aloia et al.,
Cohen’s d = 0.40, representing an improvement of 20 mi-
nutes per night assuming the SD of the improvement to
be 60 minutes (in paired/cross-over studies SD is usually
smaller than that in unpaired studies). With set power =
80 % and alpha = 5 % (2-sided), to test an effect size d =
0.40 we will need 100 subjects each with high and low
nasal resistance, based on the method of a 2-sample t test
with equal variance. With a total of 400 subjects, we have
enough power to test this hypothesis.
To determine if the benefit of CPAPFlex on adherence
will be greatest if it is offered at CPAP initiation rather
than as a “rescue” therapy in subjects with high nasal
resistance, we expect that 200 subjects will have high nasal
resistance and half (100) of them will receive CPAPFlex at
the initiation of treatment per randomization. Using the
method of a 2-sample t test, we will have 80 % power
(alpha = 0.05, 2-sided) to test a difference of 23.9 minutes
(SD = 60 minutes) in improvement between subjects with
high nasal resistance and CPAPFlex versus CPAP at initi-
ation. After accounting for 40 % CPAP rejection, we will
be able to test a difference of 27.6 minutes (SD = 60 mi-
nutes) in the CPAPFlex improvement.
Statistical analysis plan
To determine if high nasal resistance is associated with
decreased CPAP adherence we will first explore the dis-
tributions of nasal resistance and adherence of CPAP
(number of hours/night), both in continuous scale and
the discrete scale (nasal resistance (high versus low at
the cutoff of log[Reff] = 0.8); CPAP rejection (rejection
“yes” versus “no” at a cutoff of 2 hours/night). We will
calculate the correlation between nasal resistance and
CPAP when both are treated as continuous measures,
and use the chi-square test when both are discrete vari-
ables. To control for age, gender, BMI, and AHI we will
use the linear regression (in continuous case) and logis-
tic regression (in discrete case) analyses as we evaluate
these associations. To determine if the use of CPAPFlex
will improve adherence with CPAP in subjects with high
nasal resistance, but not in those with low nasal resist-
ance, we will use mixed model analysis for repeated
measures resulting from the cross-over design. Specific-
ally, we will use the average hours of CPAP/CPAPFlex
use over the last 2 weeks in each phase as the dependent
variable. Treatment assignment (CPAP versus CPAPFlex),
nasal resistance (high versus low according to the cutoff
of log[Reff] = 0.8) and their interaction will be modeled
as fixed effects in the statistical model and the intra-
subject correlation between repeated measures will be
modeled using random effects. If the use of CPAPFlex
improves adherence to CPAP in subjects with high nasal
resistance, but not in those with low nasal resistance, we
expect to observe a significant interaction of treatment
assignment and nasal resistance. Linear contrasts will
also be constructed to evaluate improvement with
CPAPFlex in subjects with high and low nasal resistance
separately. Variables such as age, gender, BMI, AHI, etc.,
will be further controlled for in these statistical analyses.
Finally, to determine if the benefit of CPAPFlex on ad-
herence will be greatest if it is offered at CPAP initiation
rather than as a “rescue” therapy in subjects with high
nasal resistance, we will use linear regression analysis
with the difference in the average use between CPAP
and CPAPFlex as the dependent variable, treatment se-
quence (CPAP followed by CPAPFlex versus CPAPFlex
followed by CPAP), nasal resistance (high versus low)
and their interaction as the independent variables. If the
benefit of CPAPFlex is greatest when it is offered at initi-
ation in subjects with high nasal resistance, we expect
the interaction of treatment sequence and nasal resist-
ance to be significant. Linear contrasts will also be con-
structed to evaluate improvement with CPAPFlex for
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each combination of treatment sequence and nasal resist-
ance separately. If a substantial proportion of subjects re-
ject CPAP and/or CPAPFlex and results in excessive zeros
(or low numbers close to zero) in the data, we will use the
two-part model [35, 36] to analyze the data. In general,
the term two-part model refers to having both a logistic
model part to model the probability of non-zero versus
zero outcomes (part 1) and a linear model part for the
values of the non-zero outcomes (part 2). In our study, we
will use the logistic model part to model the probability of
rejection (defined by total CPAP/CPAPFlextime < 2 hours,
“yes”/”no”), and the linear model part to model the aver-
aged daily use in hours after excluding those who reject.
Treatment assignment (CPAP versus CPAPFlex), nasal
resistance (high versus low) and their interaction will be
the independent variables in both model parts. Each
hypothesis will be tested using either the score or the
Wald test [36]. Subgroup analyses will be performed based
on (i) sleep apnea severity (mild sleep apnea – AHI4% 5
to ≤ 15/hour and moderate/severe sleep apnea – AHI4% >
15/hour), (ii) baseline sleepiness (ESS < 10 and ≥ 10), (iii)
excluding subjects who are using sedative drugs.
Discussion
The present study is one arm of a larger study of WTC re-
sponders where the relationship of nasal pathology to
OSA is being examined. We hope to recruit 1000 subjects
for the larger study, 400 of whom with OSA will par-
ticipate in the RCT of CPAP versus CPAPFlex. The RCT
portion of the study should have broad impact on the
management of OSA potentially caused by upper airway
pathology resulting from toxic inhalation of WTC dust.
We are using a validated portable monitor to evaluate
large numbers of subjects specifically for the presence of
OSA. We are addressing the important specific question
of whether nasal pathology negatively impacts on the abil-
ity to use CPAP, with the potential that addressing this
with modified CPAP will improve the therapeutic ap-
proach to OSA. The study is being performed in collabor-
ation with the NYUSOM CCE for Responders (principal
investigator (PI) Denise Harrison, MD) which follows 2100
subjects and EOHSI, Rutgers RWJMS, Piscataway (PI Iris
Udasin, MD) which follows 1700 responders. The study
will generate new knowledge about conditions common in
WTC exposed individuals, including nasal pathology and
OSA. By using a less costly but equally effective evaluation
of sleep disordered breathing (limited channel portable
monitoring) and automated CPAP initiation [37–39] it will
improve access to care for individuals exposed to WTC
dust. The objective measures of nasal resistance measure-
ments will help answer whether the OSA is attributable to
nasal consequences of WTC exposure. Adherence and ef-
ficacy of different therapies will be evaluated providing
guidelines to physicians caring for these patients.
Trial status
The trial is currently ongoing and subjects are being ac-
tively recruited for the study.
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